Welcome back to Biotech Blueprint!In this week’s special episode, I teamed up with the Biotech Capital Compass to examine where gene editing stands today, scientifically, commercially, and clinically. This marks the start of a multi-part series on gene therapies, viewed through both scientific and investment lenses.Subscribe to Biotech Blueprint and Biotech Capital Compass.